189 related articles for article (PubMed ID: 19401448)
1. Heregulin regulates prolactinoma gene expression.
Vlotides G; Cooper O; Chen YH; Ren SG; Greenman Y; Melmed S
Cancer Res; 2009 May; 69(10):4209-16. PubMed ID: 19401448
[TBL] [Abstract][Full Text] [Related]
2. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.
Vlotides G; Siegel E; Donangelo I; Gutman S; Ren SG; Melmed S
Cancer Res; 2008 Aug; 68(15):6377-86. PubMed ID: 18676863
[TBL] [Abstract][Full Text] [Related]
3. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.
Fukuoka H; Cooper O; Mizutani J; Tong Y; Ren SG; Bannykh S; Melmed S
Mol Endocrinol; 2011 Jan; 25(1):92-103. PubMed ID: 21106881
[TBL] [Abstract][Full Text] [Related]
4. Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.
Bhat-Nakshatri P; Sweeney CJ; Nakshatri H
Oncogene; 2002 Mar; 21(13):2066-78. PubMed ID: 11960379
[TBL] [Abstract][Full Text] [Related]
5. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
6. Endogenous expression of Neuregulin-1 (Nrg1) as a potential modulator of prolactin (PRL) secretion in GH3 cells.
Zhao W; Shen Y; Ren S
Cell Tissue Res; 2011 May; 344(2):313-20. PubMed ID: 21437657
[TBL] [Abstract][Full Text] [Related]
7. Loss of 15-hydroxyprostaglandin dehydrogenase indicates a tumor suppressor role in pituitary adenomas.
Bai JW; Wang Z; Gui SB; Zhang YZ
Oncol Rep; 2012 Aug; 28(2):714-20. PubMed ID: 22580984
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting MAPK14 showed anti-prolactinoma effect.
Ding QY; Zhang Y; Ma L; Chen YG; Wu JH; Zhang HF; Wang X
BMC Endocr Disord; 2020 Sep; 20(1):138. PubMed ID: 32894113
[TBL] [Abstract][Full Text] [Related]
9. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
10. Heregulin-stimulated signaling in rat pheochromocytoma cells. Evidence for ErbB3 interactions with Neu/ErbB2 and p85.
Gamett DC; Greene T; Wagreich AR; Kim HH; Koland JG; Cerione RA
J Biol Chem; 1995 Aug; 270(32):19022-7. PubMed ID: 7642563
[TBL] [Abstract][Full Text] [Related]
11. ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.
Liu X; Kano M; Araki T; Cooper O; Fukuoka H; Tone Y; Tone M; Melmed S
Endocrinology; 2015 Jan; 156(1):71-9. PubMed ID: 25375038
[TBL] [Abstract][Full Text] [Related]
12. Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase.
Vijapurkar U; Cheng K; Koland JG
J Biol Chem; 1998 Aug; 273(33):20996-1002. PubMed ID: 9694850
[TBL] [Abstract][Full Text] [Related]
13. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.
Bourguignon LY; Gilad E; Peyrollier K
J Biol Chem; 2007 Jul; 282(27):19426-41. PubMed ID: 17493932
[TBL] [Abstract][Full Text] [Related]
14. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
15. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
Cooper O; Mamelak A; Bannykh S; Carmichael J; Bonert V; Lim S; Cook-Wiens G; Ben-Shlomo A
Endocrine; 2014 Jun; 46(2):318-27. PubMed ID: 24287797
[TBL] [Abstract][Full Text] [Related]
16. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
17. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
18. Heregulin stimulates mitogenesis and phosphatidylinositol 3-kinase in mouse fibroblasts transfected with erbB2/neu and erbB3.
Carraway KL; Soltoff SP; Diamonti AJ; Cantley LC
J Biol Chem; 1995 Mar; 270(13):7111-6. PubMed ID: 7535767
[TBL] [Abstract][Full Text] [Related]
19. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
Vijapurkar U; Kim MS; Koland JG
Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
[TBL] [Abstract][Full Text] [Related]
20. Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells.
Watters JJ; Chun TY; Kim YN; Bertics PJ; Gorski J
Mol Endocrinol; 2000 Nov; 14(11):1872-81. PubMed ID: 11075818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
